DEP114

Phase 3Small molecule

EEMS

DEP114 is one of 41 small molecule programs targeting Allergic Rhinitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allergic RhinitisNot yet recruiting

Allergic RhinitisPhase 3

Not yet recruiting

Competition

Competitive Landscape

52 competitors in Allergic Rhinitis

#DrugCompanyPhaseTrials

Singulair

OOrganon and Co

Approved

13 2

Flovent

PParatek Pharmaceuticals Inc

Approved

12 3

Xyzal

CChattem

Approved

11 4

Alvesco

AAzurity Pharmaceuticals

Approved

8 5

Claritin

PPerrigo Company

Approved

6 6

Zyrtec

KKenvue Brands

Approved

5 7

Pulmicort

SSalix

Approved

5 8

Clarinex

OOrganon and Co

Approved

5 9

Qvar

SSchering-Plough

Approved

4 10

Allegra

CChattem

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Not yet recruiting

Allergic Rhinitis

NCT06272409

Clinical

Trials by Indication[1]

Allergic Rhinitis1 trial

Efficacy and Safety of DEP114 in the Treatment of Moderate to Severe Persistent Allergic Rhinitis in Children.

Not yet recruiting·EEMS·Phase 3·NCT06272409·318 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DEP114. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DEP114 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DEP114. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EMS company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEMS

DEP114

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Allergic Rhinitis1 trial

References

Drug Info

Quick Facts

Related News